Floatz logo

Tebotelimab

Advanced Hepatocellular Carcinoma (HCC)

Zai Lab (Shanghai) Co., Ltd.monoclonal_antibodyPhase 1/2Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

521 Active assets in the Advanced Hepatocellular Carcinoma (HCC) cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Tebotelimab is also rated in:

hematopoietic and lymphoid system neoplasmDormant
D
Indicative ·
29 / 100
View asset →
metastatic neoplasmDormant
D
Indicative ·
29 / 100
View asset →
small cell lung carcinomaDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →